HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    
FREE winning picks
Quote:
Login
Search:

Top Zacks Features
Free Membership
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
Zacks Trading Game
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Surprise Trader
Top 10 Stocks
Value Trader
Value Trader 2
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration
Receive Special Offers                  Privacy Policy
Close This Panel X

AMAG: Amag Pharmaceuticals Inc - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

AMAG PHARMACEUTICALS INC (NASD)
AMAG 52.81 -3.10 (-5.54%) Vol.  869,336 15:59 ET

Day Low - High 52.59 - 55.49
52wk Low - High 18.33 - 58.23
Avg Volume 549,465
Industry MED INSTRUMENTS
Market Cap 899.04 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -5.07
EPS Last Year -5.22
Detailed Quote


Zacks Premium Research
Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank

Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations

Zacks Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

Rank in Industry

By clicking on the Rank in Industry link you will see best companies in the industry as judged by the Zacks Rank.

Zacks Rank Education - Learn more about the Zacks Rank
Zacks Premium - The only way to get access to the Zacks Rank and Rank in Industry

Zacks Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations



BROKERAGE RECOMMENDATIONS
Current ABR 1.40
ABR (Last Week) N/A
# of Recs in ABR 10
Average Target Price 62.70
Industry Rank by ABR 54 out of 217
Rank in Industry 10 out of 45
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate AMAG?
Buy
Sell
Find out what the Zacks Community
thinks of AMAG at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart
 New: Zacks Trading Game



NEWS FOR AMAG
Jul 02, 2009 17:00 Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and Montpelier
Jul 01, 2009 11:57 LiquidTycoon.com: Borland Software Corporation (NASDAQ:BORL) ) is the Highest Percentage Gainers Among NASDAQ Stocks During Morning Trading Hours
Jul 01, 2009 08:25 Comtex SmarTrend(R) Morning Call -- July 1, 2009
Jul 01, 2009 07:32 SmarTrend(R) News Watch: AMAG Pharma Gets FDA Approval on Kidney Treatment
Jul 01, 2009 05:59 AMAG: Conference call regarding To Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients @ 08:30 ET Today [delayed]
More News

ZACKS COMMENTARY FOR AMAG
Jul 02, 2009 Bull of the Day: AMAG Pharmaceuticals (AMAG)
Jul 01, 2009 Zacks Blog: FDA Approves AMAG’s Feraheme
Jul 01, 2009 Zacks Equity Research: Report for AMAG
Jun 19, 2009 Zacks Blog: AMAG Awaits FDA Decision
Jun 01, 2009 Zacks Analyst Interviews: Biotech Industry
More Commentaries

EARNINGS ESTIMATES
  This Quarter
06/2009
Next Quarter
09/2009
This Year
12/2009
Next Year
12/2010
Average Estimate -1.50 -1.20 -5.07 -0.04
Number of Estimates 9 9 10 8
Low Estimates -1.72 -1.68 -6.34 -2.13
High Estimate -1.22 -0.57 -3.68 2.27
Year Ago EPS -1.00 -1.39 -4.22 -5.07
EPS Growth -49.78% 13.83% -20.05% 99.21%

More Estimates

COMPANY DESCRIPTION
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.

Full Company Report
FINANCIALS
EPS TTM -5.22
Sales 1.94
Net Income -88.77
Price/Earnings N/A
Price/Book 4.66
Price/Cash Flow N/A
Price/Sales 393.97


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research